GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aerie Pharmaceuticals Inc (NAS:AERI) » Definitions » Interest Coverage

Aerie Pharmaceuticals (Aerie Pharmaceuticals) Interest Coverage : 0 (At Loss) (As of Sep. 2022)


View and export this data going back to 2013. Start your Free Trial

What is Aerie Pharmaceuticals Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Aerie Pharmaceuticals's Operating Income for the three months ended in Sep. 2022 was $-26.7 Mil. Aerie Pharmaceuticals's Interest Expense for the three months ended in Sep. 2022 was $-1.7 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Aerie Pharmaceuticals's Interest Coverage or its related term are showing as below:


AERI's Interest Coverage is not ranked *
in the Drug Manufacturers industry.
Industry Median: 12.09
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Aerie Pharmaceuticals Interest Coverage Historical Data

The historical data trend for Aerie Pharmaceuticals's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Aerie Pharmaceuticals Interest Coverage Chart

Aerie Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Aerie Pharmaceuticals Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 6.88 - - -

Competitive Comparison of Aerie Pharmaceuticals's Interest Coverage

For the Drug Manufacturers - Specialty & Generic subindustry, Aerie Pharmaceuticals's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aerie Pharmaceuticals's Interest Coverage Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aerie Pharmaceuticals's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Aerie Pharmaceuticals's Interest Coverage falls into.



Aerie Pharmaceuticals Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Aerie Pharmaceuticals's Interest Coverage for the fiscal year that ended in Dec. 2021 is calculated as

Here, for the fiscal year that ended in Dec. 2021, Aerie Pharmaceuticals's Interest Expense was $-28.9 Mil. Its Operating Income was $-46.4 Mil. And its Long-Term Debt & Capital Lease Obligation was $256.3 Mil.

Aerie Pharmaceuticals did not have earnings to cover the interest expense.

Aerie Pharmaceuticals's Interest Coverage for the quarter that ended in Sep. 2022 is calculated as

Here, for the three months ended in Sep. 2022, Aerie Pharmaceuticals's Interest Expense was $-1.7 Mil. Its Operating Income was $-26.7 Mil. And its Long-Term Debt & Capital Lease Obligation was $332.1 Mil.

Aerie Pharmaceuticals did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Aerie Pharmaceuticals  (NAS:AERI) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Aerie Pharmaceuticals Interest Coverage Related Terms

Thank you for viewing the detailed overview of Aerie Pharmaceuticals's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Aerie Pharmaceuticals (Aerie Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
4301 Emperor Boulevard, Suite 400, Durham, NC, USA, 27703
Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases, and retinal diseases. Its main products are Rhopressa and Roklatan. The company mainly operates in North America.
Executives
Peter Frederick Lang officer: Chief Financial Officer AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Raj Kannan director, officer: Chief Executive Officer C/O CHIASMA, INC. 460 TOTTEN POND RD, SUITE 530, WALTHAM MA 02451
Jeffrey Calabrese officer: Vice President of Finance AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Kathleen Mcginley officer: CHRO & VP, Corp Services 15279 ALTON PARKWAY SUITE 100, IRVINE CA 92618
Christopher Staten officer: Interim CFO AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Casey C. Kopczynski officer: Chief Scientific Officer 135 U.S. HIGHWAY 206, SUITE 15, BEDMINSTER NJ 07921
Peter J Mcdonnell director 2525 DUPONT DRIVE, IRVINE CA 92612
Gerald D. Cagle director 135 U.S. HIGHWAY 206, SUITE 15, BEDMINSTER NJ 07921
Foresite Capital Fund Ii, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
David Hollander officer: Chief R&D Officer C/O AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Richard J Rubino officer: Chief Financial Officer
Vicente Jr Anido director, officer: Chief Executive Officer 1621 BAYSIDE DR, CORONA DEL MAR CA 92625
Foresite Capital Management Iv, Llc 10 percent owner 900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939
Foresite Capital Fund Iv, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Thomas A Mitro officer: President and COO 15279 ALTON PARKWAY SUITE #100, IRVINE CA 92618

Aerie Pharmaceuticals (Aerie Pharmaceuticals) Headlines

From GuruFocus

Aerie Pharmaceuticals Announces New Employee Inducement Grant

By Business Wire Business Wire 07-08-2022